ReviewBriefings in bioinformatics2019
Disease prediction by cell-free DNA methylation.
Review in Briefings in bioinformatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- DNA methylation heterogeneity in complex tumor microenvironment: Quantitative methods, influencing factors, and clinical implications.Genes & diseases · 2026Review
- Value of circulating free DNA methylation in the diagnosis of esophageal cancer: A systematic review and meta-analysis.Oncology letters · 2025Article
- Review
- Whole-genome bisulfite sequencing of cell-free DNA unveils age-dependent and ALS-associated methylation alterations.Cell & bioscience · 2025Article
- cfTools: an R/Bioconductor package for deconvolving cell-free DNA via methylation analysis.Bioinformatics advances · 2025Article
- Reference-free deconvolution of complex samples based on cross-cell-type differential analysis: Systematic evaluations with various feature selection options.Frontiers in genetics · 2025Article
- Transformer-based representation learning and multiple-instance learning for cancer diagnosis exclusively from raw sequencing fragments of bisulfite-treated plasma cell-free DNA.Molecular oncology · 2024Article
- LABS: linear amplification-based bisulfite sequencing for ultrasensitive cancer detection from cell-free DNA.Genome biology · 2024Article
- Distinctive cell-free DNA methylation characterizes presymptomatic genetic frontotemporal dementia.Annals of clinical and translational neurology · 2024Article
- Blood biomarkers of hepatocellular carcinoma: a critical review.Frontiers in cell and developmental biology · 2024Review
- Integrative analysis of DNA methylomes reveals novel cell-free biomarkers in lung adenocarcinoma.Frontiers in genetics · 2023Article
- Environmental DNA methylation of Lymnaea stagnalis varies with age and is hypermethylated compared to tissue DNA.Molecular ecology resources · 2023Article
- Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis.Nature communications · 2022Article
- Article
- Cell-free DNA methylation as a potential biomarker in brain disorders.Epigenomics · 2022Article
- Computational challenges in detection of cancer using cell-free DNA methylation.Computational and structural biotechnology journal · 2022Review
- The Potential of Circulating Cell-Free DNA Methylation as an Epilepsy Biomarker.Frontiers in cellular neuroscience · 2022Review
- DISMIR: Deep learning-based noninvasive cancer detection by integrating DNA sequence and methylation information of individual cell-free DNA reads.Briefings in bioinformatics · 2021Article
- Role of blood mSEPT9 in evaluating tumor burden and disease monitoring in colorectal cancer patients.Journal of clinical laboratory analysis · 2021Article
- Detection of Cell Types Contributing to Cancer From Circulating, Cell-Free Methylated DNA.Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Disease diagnosis using cell-free DNA (cfDNA) has been an active research field recently. Most existing approaches perform diagnosis based on the detection of sequence variants on cfDNA; thus, their applications are limited to diseases associated with high mutation rate such as cancer. Recent developments start to exploit the epigenetic information on cfDNA, which could have substantially wider applications. In this work, we provide thorough reviews and discussions on the statistical method developments and data analysis strategies for using cfDNA epigenetic profiles, in particular DNA methylation, to construct disease diagnostic models. We focus on two important aspects: marker selection and prediction model construction, under different scenarios. We perform simulations and real data analysis to compare different approaches, and provide recommendations for data analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.